Role of BATAN in Preparing Radioisotopes

and Radiopharmaceuticals for Cancer

Diagnosis and Treatment in Indonesia

Abdul Mutalib
Center for Radioisotopes and Radiopharmaceuticals
National Atomic Energy Agency (BATAN)
BATAN and PT Batantek

 BATAN A Government R&D Institution

 PT Batantek A Government owned Company

BATAN has the following functions :

• To assess and prepare the national policy in the field of research,

development, and the beneficial uses of nuclear energy.

• To develop and utilize production

technology of radioisotopes and
radiopharmaceuticals for healthcare.
Technology of radioisotope production
• Radiotherapy
137Cs, 60Co

Sealed Sources)
• Brachytherapy
125I, 103Pd, 192Ir,
198Au

Cyclotron CS30 Radioisotopes/

Radionuclides
• Radiopharmaceutic
als
• Radionuclide
Unsealed-Sources) Generators
• Radioassay Kits
• Molecular
Nuclear Reactor Radiotracers
Brachytherapy Sources developed by BATAN

 125I-seed brachytherapy

 125I-thermosensitive polymer

 198Au-Nanodevice brachytherapy

 192Ir HDR/LDR brachytherapy

 Physical Characteristics of Brachytherapy Sources

Physical
Radionuclide Half-life E (KeV) Configuration Remarks

Iodine-125 60 d 35 Seeds Small size; less

exposure to personnel
Gold-198 2.7 d 412 nanodevice Small size; higher dose
rate
Palladium-103 17 d 23 Seeds Small size; higher dose
rate; less exposure to
personnel
Iridium-192 74 d 136 – 1060 Wire, seeds, Wide variety of source
cathethers strengths and sizes;
(afterloading) usually afterloaded
The BATAN’s Facility for Producing Radionuclide of 125I
BATAN’s Laser Welder for preparing 125I and 103Pd seed and 192Ir
needle sealed-sources
 125I seed sealed-sources

Brachytherapy of Prostate
Cancer using 125I seeds
Development of Target-Specific Radiopharmaceuticals
(Molecular Targeting Agents)

18F, 123I,
124I,11C, Non-Metalic
Targeting Molecule
131I, 211At
Radionuclide
67Cu, 90Y,
99mTc, 188Re,
186Re, 166Ho,
177Lu

Metalic
Radionuclide Targeting Molecule

Bifunctional Linker
Chelating (Pharmacokinetic Modifier)
Agent
Requirements for target-specific
radiopharmaceuticals

• Suitable radionuclide Targeting

for imaging and therapy Molecule
with stable linkage to
the targeting molecule Molecular
Target

Targeting Cancer Cell

Molecule

• Targeting molecule
with specific binding
to the target structure
(tumor, infection, etc)
Radiopharmaceuticals for Molecular Imaging
Hospitals
RPs of
18F,124I,
18F,124I, GMP Based 96Zr, 64Cu
96Zr,123I, Radiopharmaceutical
111In, 64Cu Production Facility

PET-CT

Cyclotron CS30

99mTc,
RPs of
123I,111In,
131I
99mTc, 131I

RPs= Radiopharmaceuticals
Nuclear Reactor SPECT-CT
Radiopharmaceuticals developed by BATAN for
Nuclear Oncology:
• PET and SPECT radiopharmaceuticals, such as 18FDG, 18FLT, 123I-
MIBG, 99mTc-HYNIC Octreotide, 99mTc-HYNIC-Folate, etc.
• Therapeutic radiopharmaceuticals:
- 153Sm-EDTMP
- 186Re-HEDP
- 131I-MIBG
- 131I-Lipiodol
- 177Lu-DOTA-Nimotuzumab
177Lu-DOTA-Trastuzumab
Radioimmunotherapy
-
• 90Sr/90Y Therapeutic Generator
• PZC-Based 188W/188Re Therapeutic Generator
RIA Kits developed by BATAN for Nuclear
Oncology:

• IRMA Kit CA 125 for in vitro diagnosis of

ovarium cancer

• IRMA Kit CA 15.3 for in vitro diagnosis of

breast cancer
PACT Fundamentals
• National Cancer Control Programs:
 Prevention
 Early Detection
 Diagnosis and Treatment
 Palliative Care

• Radiation Medicine and the role of the BATAN and the IAEA
* Radiation Medicine includes both radiotherapy (or radiation
oncology) and diagnostic imaging involving the safe use of ionizing
radiation and nuclear medicine procedures.
BATAN’s Role for PACT/Nuclear Oncology:

• Conducts R&D on radiopharmaceuticals, RIA/IRMA Kits, and

brachytherapy sealed sources for PACT

• Provides production technology packages of radioisotopes and

radiopharmaceuticals developed by BATAN to be implemented by
national companies, such as PT Kimia Farma, PT Batantek, for
fullfiling national needs.
 Program Action BATAN’s Contribution

• Early Detection • Develop RIA/IRMA Kits, PET and SPECT

radiopharmaceuticals as required by
Hospitals
• Diagnosis • Develop PET and SPECT
radiopharmaceuticals as required by
Hospitals
• Treatment or Therapy • Develop sealed sources (needle, seed) for
HDR and LDR Brachytherapy, CND
Brachytherapy, Targeted Therapeutic
Radiopharmaceuticals
• Palliative Care • Develop simple and targeted therapeutic
radiopharmaceuticals
Summary
• BATAN will actively involve to support PACT through the R&D
programs.

• BATAN will encourage a close relationship and communication

between BATAN’s institutes with hospitals/medical doctors to
develop radiopharmaceuticals/RIA and IRMA Kits, brachytherapy
sealed sources for suitable for local condition.
Thank you